Arcus Biosciences Inc. (RCUS) Financial Statements (2025 and earlier)

Company Profile

Business Address 3928 POINT EDEN WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments759,0001,009,000499,308173,41557,93771,064
Cash and cash equivalents127,000206,000147,914173,41557,93771,064
Short-term investments632,000803,000351,394   
Receivables4,0004,0002,2271,592 83
Contract with customer, asset, after allowance for credit loss38,00039,000744,5951,049132 
Other undisclosed current assets30,00015,00015,620559,759134,636187,801
Total current assets:831,0001,067,0001,261,750735,815192,705258,948
Noncurrent Assets
Operating lease, right-of-use asset   104,96812,781 
Property, plant and equipment51,00035,00032,45510,8079,33011,107
Long-term investments and receivables107,000129,000181,9906,440 1,202
Long-term investments107,000129,000181,9906,440 1,202
Restricted cash and investments   3,005203203203
Other noncurrent assets106,000114,0007,7306,246872284
Other undisclosed noncurrent assets      3,181
Total noncurrent assets:264,000278,000330,14836,47710,40515,977
TOTAL ASSETS:1,095,0001,345,0001,591,898772,292203,110274,925
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities17,00020,00052,90533,85714,2269,125
Taxes payable1,815   
Employee-related liabilities16,6488,632  
Accounts payable17,00020,00010,26115,6824,7043,102
Accrued liabilities   24,1819,5439,5226,023
Deferred revenue91,00097,000102,00374,5717,000
Other liabilities76,00076,000523,5661,4801,560
Other undisclosed current liabilities   11,1249,675 6,250
Total current liabilities:184,000193,000166,084121,66922,70616,935
Noncurrent Liabilities
Long-term debt and lease obligation:   116,88715,243  
Liabilities, other than long-term debt449,000495,000467,477133,07616,5626,064
Deferred revenue307,000355,000462,217122,83012,022
Deferred rent credit     3,7344,272
Other liabilities142,000140,0005,26010,2468061,792
Operating lease, liability   116,88715,243 
Other undisclosed noncurrent liabilities      16,984
Total noncurrent liabilities:449,000495,000584,364148,31916,56223,048
Total liabilities:633,000688,000750,448269,98839,26839,983
Equity
Equity, attributable to parent462,000657,000841,450502,304163,842234,942
Common stock1,311,0001,206,0007644
Additional paid in capital   1,118,058830,438369,100357,873
Accumulated other comprehensive income (loss) (7,000)(1,261)4464(107)
Accumulated deficit(849,000)(542,000)(275,354)(328,184)(205,326)(122,828)
Total equity:462,000657,000841,450502,304163,842234,942
Other undisclosed liabilities and equity      
TOTAL LIABILITIES AND EQUITY:1,095,0001,345,0001,591,898772,292203,110274,925

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues117,000112,000382,88277,51715,0008,353
Gross profit:117,000112,000382,88277,51715,0008,353
Operating expenses(457,000)(392,000)(328,634)(201,752)(103,709)(63,212)
Operating income (loss):(340,000)(280,000)54,248(124,235)(88,709)(54,859)
Nonoperating income39,00014,0003971,3773,9995,265
Interest and debt expense      
Income (loss) from continuing operations before equity method investments, income taxes:(301,000)(266,000)54,645(122,858)(84,710)(49,594)
Loss from equity method investments    (613)  
Other undisclosed income from continuing operations before income taxes      
Income (loss) from continuing operations before income taxes:(301,000)(266,000)54,645(123,471)(84,710)(49,594)
Income tax expense(6,000)(1,000)(1,815)   
Income (loss) from continuing operations:(307,000)(267,000)52,830(123,471)(84,710)(49,594)
Income (loss) before gain (loss) on sale of properties:52,830(123,471)(84,710)(49,594)
Other undisclosed net income    613  
Net income (loss) available to common stockholders, diluted:(307,000)(267,000)52,830(122,858)(84,710)(49,594)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(307,000)(267,000)52,830(122,858)(84,710)(49,594)
Other comprehensive income (loss)7,000(6,000)(1,305)(20)171(65)
Other undisclosed comprehensive income      
Comprehensive income (loss):(300,000)(273,000)51,525(122,878)(84,539)(49,659)
Other undisclosed comprehensive loss, net of tax, attributable to parent      
Comprehensive income (loss), net of tax, attributable to parent:(300,000)(273,000)51,525(122,878)(84,539)(49,659)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: